Navigation Links
MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
Date:4/12/2011

eatment  
  • There was no statistical difference in PASP between the LEVADEX and placebo groups over two hours
  • No significant electrocardiogram (ECG) changes were observed
  • Adverse events were more frequent in the IV DHE group than in the LEVADEX or placebo groups

  • The three additional LEVADEX related presentations are:
    Utility of LEVADEX (MAP0004) in Situations Where Early Intervention Paradigm Is Impractical
    Session Info: Platform Session: April 12, 2011, 3:00-4:30 p.m. HAST
    Presentation Info: April 12, 2011 at 3:45 p.m. HAST
    Presentation #: 004

    This presentation has been selected by the Scientific Program Subcommittee to be in the top five percent of the American Academy of Neurology presentations and, as such, LEVADEX will be highlighted by the Subcommittee during the Scientific Program Highlights Plenary Session on Friday, April 15, 5:15 – 6:15 p.m.

    The Major Metabolite of Dihydroergotamine (DHE) after Oral Inhalation and IV Administration Does Not Significantly Contribute to the Pharmacologic Activity
    Session Info: Poster Session 5: April 13, 2011, 2:00-6:30 p.m. HAST
    Poster #: 272

    Migraine Recurrence Rates: Case for Standardization of the Definition
    Session Info: Poster Session 5: April 13, 2011, 2:00-6:30 p.m. HAST
    Poster #: 285

    About LEVADEX® LEVADEX is an investigational acute drug for migraine that has completed Phase 3 clinical development.  In the clinical trial, patients administered LEVADEX themselves using the proprietary TEMPO® inhaler.  LEVADEX contains a novel formulation of dihydroergotamine (DHE).  LEVADEX was evaluated in the efficacy portion of FREEDOM-301, MAP Pharmaceuticals' Phase 3 pivotal trial, which included 395 patients in the LEVADEX arm and 397 patients in the placebo arm.  In the Phase 3 trial, patients taking LEVADEX had statistically significant improvement at two hours compared to patients on placebo fo
    '/>"/>

    SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2014)... 23, 2014  SI-BONE, Inc., a medical device company ... ® a minimally invasive surgical (MIS) device indicated ... that the U.S. Patent and Trademark Office has awarded ... for the fixation and fusion of bone.  This newly ... tapered distal end that may be placed from one bone across ...
    (Date:9/23/2014)... Sept. 23, 2014 Report Details ... you trends, R&D and predicted revenues Do you ... Now get the latest analysis for those cancer ... opportunities and revenue forecasts. Visiongain,s new report ... kinase inhibition and related technology. There avoid missing ...
    (Date:9/23/2014)... , Sept. 23, 2014 EnzymeBioSystems (OTCBB: ... along with the process of evaluating an enzyme ... in fighting tumors. In an effort to evaluate this ... with various contract research organizations to enlist their ... the use of an antitumor natural product called ...
    Breaking Medicine Technology:SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 2Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 4Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 5EnzymeBioSystems Announces Progress with an Enzyme Compound 2
    ... today reported financial results for the third quarter ended,September ... Novavax reported a net loss of $9.0 million, or ... $5.0 million net loss, or the,equivalent of $0.08 loss ... For the nine months ended September 30, 2007, the ...
    ... Allos,Therapeutics, Inc. (Nasdaq: ALTH ) today announced ... non-randomized, open-label, multi-center dose,escalation study of the Company,s ... tumors or non-Hodgkin,s lymphoma (NHL). "We are ... said Pablo,J. Cagnoni, M.D., Chief Medical Officer of ...
    Cached Medicine Technology:Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 2Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 3Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 4Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 5Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 6Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 2Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 3Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 4
    (Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- A test used ... geographic regions where certain lung infections are more common, a ... lung cancer is through the use of what,s known as ... imaging called FDG-PET is used, according to the study authors. ... do parts of the lungs that don,t have ...
    (Date:9/23/2014)... Avid collector Andrew Hawley, from Vintage Rock Posters, ... Seattle concert posters. The Doors were a smash hit after ... The Seattle Eagles Auditorium concert was held on July 23. ... Eagles Auditorium in November the same year. The artist that ... in three colors. The poster is a split fountain silkscreen ...
    (Date:9/23/2014)... What: Rutgers Presbyterian Church, a ... that embodies the inclusion and diversity of New ... the Ecological Crisis, a public lecture led by ... of Old Testament at Louisville Presbyterian Seminary. Tull ... lends insight into current ecological problems, including energy ...
    (Date:9/23/2014)... A recent Oregon survey about an exercise DVD ... daily routine of elementary school students found it had ... teachers, and offered clear advantages for overly sedentary educational ... and produced by the Healthy Youth Program of the ... available nationally. , Brain Breaks leads children in 5-7 ...
    (Date:9/23/2014)... OAK BROOK, Ill. (September 23, 2014) Both ... malignancy with screening computed tomography (CT) colonography greatly ... invasive follow-up tests precipitated by false-positive diagnoses, according ... issue of the journal Radiology . , ... target a specific organ. However, when screening for ...
    Breaking Medicine News(10 mins):Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 3Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3
    ... Completes Renovation of Local ... Pediatrician,s Office, HOUSTON, Dec. ... Office Makeover" for pediatrician Dr.,Muhammad Shaikh at the Bissonet Medical Center ... initiative that AMERIGROUP Community,Care sponsored for the area,s physicians and its ...
    ... Aida,Pharmaceuticals (OTC Bulletin Board: AIDA) today ... has been named as a "New and,High-Tech ... New High,Technology Service Centre ("SNHTSC"), a special ... Government. This,designation will allow Rh-Apo2L to have ...
    ... and Treat Alzheimer,s Disease, MORGANTOWN, W.Va., Dec. 4 ... discovered that,a cancer drug - Bryostatin - enhances the ... This drug could potentially increase,normal memory capacity in humans ... disease, stroke and head trauma., In an article ...
    ... Proceeds Benefit Institute on Aging and the Center for ... Elderly Suicide Prevention (CESP), SAN ... at San Francisco,s War Memorial Veterans Building Green,Room, the Center for ... on Aging (IOA), celebrates their 21st Annual,Cable Car Caroling fundraising event. ...
    ... Capital Through 2010, LOUISVILLE, Ky., Dec. 4 Almost Family, ... terms of its,previously existing $22.5 million bank credit facility., ... in borrowings with a maturity date of June 2010. -- ... Earnings Before Interest Taxes Depreciation and Amortization ...
    ... Pa., Dec. 4 The Capital BlueCross Medicare,Advantage ... Keystone,Health Plan Central, was ranked as the No. ... a report issued today by the Pennsylvania,Health Care ... Containment Council is an independent state agency formed ...
    Cached Medicine News:Health News:AMERIGROUP Community Care Provides 'Doctor's Office Makeover' in Houston 2Health News:Rh-Apo2L Named as One of China's High-Tech Transforming Products by Chinese Government 2Health News:Drug Found to Create New Connections in Brain, Restoring and Improving Memory 2Health News:Carolers Bring Holiday Cheer to Homebound Seniors 2Health News:Almost Family Announces Expansion of Revolving Credit Facility 2Health News:Almost Family Announces Expansion of Revolving Credit Facility 3Health News:Capital BlueCross HMO Plan is Ranked No. 1 in Pennsylvania for Member Satisfaction 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: